DIOSynVax Announces a new Advisory Board as it drives the clinical development of its NextGen Influenza Vaccines including Bird-Flu

Posted on by

CAMBRIDGE, England and SAN DIEGO, Jan. 8, 2025 /PRNewswire/ — DIOSynVax, a clinical-stage biotechnology company at the forefront of developing innovative, broadly protective vaccines, built on the safety demonstrated by its “First in Human” Coronavirus vaccine trial, to announce its new…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.